Department of Pathology, Yale School of Medicine, New Haven, 310 Cedar St., BML348C, PO Box 208023, New Haven, CT 06520, USA.
Epigenomics. 2015;7(1):57-65. doi: 10.2217/epi.14.63.
Lysine demethylases (KDMs) are epigenetic regulators whose dysfunction is implicated in the pathology of many human diseases including various types of cancer, inflammation and X-linked intellectual disability. Particular demethylases have been identified as promising therapeutic targets, and tremendous efforts are being devoted toward developing suitable small-molecule inhibitors for clinical and research use. Several High-throughput screening strategies have been developed to screen for small-molecule inhibitors of KDMs, each with advantages and disadvantages in terms of time, cost, effort, reliability and sensitivity. In this Special Report, we review and evaluate the High-throughput screening methods utilized for discovery of novel small-molecule KDM inhibitors.
赖氨酸去甲基酶(KDMs)是表观遗传调控因子,其功能障碍与许多人类疾病的病理学有关,包括各种类型的癌症、炎症和 X 连锁智力残疾。特定的去甲基酶已被确定为有前途的治疗靶点,人们正在投入大量精力开发适合临床和研究用途的合适的小分子抑制剂。已经开发了几种高通量筛选策略来筛选 KDM 的小分子抑制剂,每种方法在时间、成本、工作量、可靠性和灵敏度方面都有其优势和劣势。在本专题报告中,我们回顾和评估了用于发现新型小分子 KDM 抑制剂的高通量筛选方法。